Table 1 Main characteristics of the non-frail study population by regular prescription polypharmacy at baseline
From: Effect modification of polypharmacy on incident frailty by chronic kidney disease in older adults
Total | No polypharmacy | Polypharmacy | Hyperpolypharmacy | |
|---|---|---|---|---|
n | 757 | 459 | 276 | 22 |
Age in years, mean (SD) | 82.9 (4.9) | 82.9 (5.0) | 82.9 (4.7) | 81.7 (3.6) |
Gender, n (%) | ||||
Female | 397 (52.4) | 250 (54.5) | 135 (48.9) | 12 (54.5) |
CASMIN, n (%) | ||||
Low | 450 (59.4) | 263 (57.3) | 173 (62.7) | 14 (63.6) |
Middle | 147 (19.4) | 94 (20.5) | 50 (18.1) | 3 (13.6) |
High | 157 (20.7) | 101 (22.0) | 51 (18.5) | 0 |
Missing | 3 (0.4) | 1 (0.2) | 2 (0.7) | 5 (22.7) |
Marital Status, n (%) | ||||
Married | 395 (52.2) | 234 (51.0) | 146 (52.9) | 15 (68.2) |
Single | 35 (4.6) | 23 (5.0) | 12 (4.3) | 0 |
Divorced | 62 (8.2) | 45 (9.8) | 17 (6.2) | 0 |
Widowed | 265 (35.0) | 157 (34.2) | 101 (36.6) | 7 (31.8) |
Smoking, n (%) | ||||
Ever | 354 (46.8) | 199 (43.4) | 140 (50.7) | 15 (68.2) |
BMI in kg/m2, n (%) | ||||
< 22 | 72 (9.5) | 57 (12.4) | 15 (5.4) | 0 |
22-<30 | 535 (70.7) | 329 (71.7) | 189 (68.5) | 17 (77.3) |
≥30 | 150 (19.8) | 73 (15.9) | 72 (26.1) | 5 (22.7) |
CCI, median [IQR] | 5 [3–7] | 4 [2–6] | 6 [5–8] | 10 [7–11] |
Missing, n (%) | 11 (1.5) | 8 (1.7) | 3 (1.1) | 0 |
CKD, n (%) | 557 (73.6) | 312 (68.0) | 224 (81.2) | 21 (95.5) |
Missing | 11 (1.5) | 8 (1.7) | 3 (1.1) | 0 |
eGFRBIS2 | ||||
mean (SD) | 52.9 (12.6) | 55.4 (11.5) | 49.5 (13.0) | 40.5 (13.1) |
Missing, n (%) | 4 (0.5) | 3 (0.7) | 0 | 1 (4.5) |
ACR, n (%) | ||||
≥ 30 mg/g | 176 (23.2) | 89 (19.4) | 81 (29.3) | 6 (27.3) |
Missing | 19 (2.5) | 12 (2.6) | 6 (2.2) | 1 (4.5) |